Ratings Bayer AG

Equities

Market Closed - Xetra Other stock markets 16:41:07 20/06/2025 BST			5-day change	1st Jan Change
26.68 ^EUR	-0.91%		-2.89%	+38.16%

06-20	German Stocks Blink Green; European Ministers to Hold Talks with Iran	MT
06-20	Bayer: towards a new indication for Nubeqa in Europe	CF

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
The opinion of analysts covering the stock has improved over the past four months.

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The group shows a rather high level of debt in proportion to its EBITDA.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	BAYER AG				30.22B
	ELI LILLY AND COMPANY				685B
	JOHNSON & JOHNSON				360B
	NOVO NORDISK A/S				326B
	ABBVIE INC.				327B
	ROCHE HOLDING AG				255B
	NOVARTIS AG				228B
	ASTRAZENECA PLC				217B
	MERCK & CO., INC.				199B
	AMGEN INC.				156B
	Average				278.22B
	Weighted average by Cap.